Immunotherapy combo tested for tough head and neck cancers

NCT ID NCT02819752

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemoradiation is safe for people with stage IV head and neck cancer. Only 3 patients were enrolled before the study was stopped. The main goal was to find the highest safe dose and track side effects, especially mouth and skin reactions from radiation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pembrolizumab (Keytruda) plus cisplatin or carboplatin chemotherapy and radiation therapy
What this could lead to
If this combination proves safe and effective, it could point toward a more powerful treatment for advanced head and neck cancer.
What could go wrong
This was a very early, small phase 1 trial that was terminated early with only 3 participants. The added side effects of combining immunotherapy with chemoradiation may outweigh any benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Royal Marsden Hospital NHS Foundation Trust

    London, SW3 6JJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.